Answers are grounded in this paper and cite their sources.
This randomized trial examines methotrexate's severe effects on bone marrow suppression, particularly in older individuals with comorbidities, highlighting significant health risks.
Methotrexate is a first line drug for Rheumatoid arthritis. It is also being used for various autoimmune diseases and in cancer as a chemotherapeutic agent for decades. It works as a folic acid antagonist in cancer. However it works by inhibiting enzyme AICAR and thereby raising intracellular adenosine in autoimmune diseases. Adverse effects can range from mild gastrointestinal disturbance to severe life-threatening pancytopenia, hepatotoxicity, infection and lymphoproliferative disorders requiring hospital admission. Before initiating this drug physician should be aware of its potential harmful effects especially in old and co-morbid patients. Complete blood count, Liver and kidney function test and serology are essential before considering this drug.
No takes yet. Share an insight, caveat, or question.
Adhikari et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: